Skip to main content
SpringerLink
Log in

Oral Prescription Therapy for Erectile Dysfunction

  • Chapter
  • First Online:
Contemporary Treatment of Erectile Dysfunction

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

The International Consultation on Sexual Medicine defined erectile dysfunction (ED) as the consistent or recurrent inability to attain and/or maintain penile erection sufficient for sexual performance. A 3-month minimum duration is accepted for establishment of the diagnosis (Recommendations of the 1st International Consultation on Erectile Dysfunction Paris, France; Health Publications Ltd, 2010). The introduction of phosphodiesterase inhibitors has greatly changed the face of sexual medicine. Prior to this, sexual issues were shrouded in mystery and ignominy. Ancient cultures have all described sexual problems. Treatments in the form of herbs, spices, tonics, potions, mixtures, magic spells, and surgery have all been presented as remedies. Not until the past 30–40 years have we been able to understand and treat sexual issues commendably. That spirit continues today as we continue to investigate the finer points of erectile dysfunction management and turn our attention to address premature ejaculation, disorders of orgasm, hypogonadism, and female sexual dysfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sturgill MG, Grasing KW, Rosen RC, et al. Yohimbine elimination in normal volunteers is characterized by both one- and two-compartment behavior. J Cardiovasc Pharmacol. 1997;29:697–703.

    Article  CAS  PubMed  Google Scholar 

  2. Piletz JE, Segraves KB, Feng YZ, Maguire E, Dunger B, Halaris A. Plasma MHPG response to yohimbine treatment in women with hypoactive sexual desire. J Sex Marital Ther. 1998;24:43–54.

    Article  CAS  PubMed  Google Scholar 

  3. Guay AT, Spark RF, Jacobson J, Murray FT, Geisser ME. Yohimbine treatment of organic erectile dysfunction in a dose-escalation trial. Int J Impot Res. 2002;14:25–31.

    Article  CAS  PubMed  Google Scholar 

  4. Pushkar D, Segal AS, Bagaev AG, Nosovitskii PB. Yohimbine in the treatment of erectile dysfunction. Urologiia. 2002;6:34–7.

    PubMed  Google Scholar 

  5. Grossman E, Rosenthal T, Peleg E, Holmes C, Goldstein DS. Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients. J Cardiovasc Pharmacol. 1993;22:22–6.

    Article  CAS  PubMed  Google Scholar 

  6. Onrot J, Goldberg MR, Biaggioni I, Wiley RG, Hollister AS, Robertson D. Oral yohimbine in human autonomic failure. Neurology. 1987;37:215–20.

    Article  CAS  PubMed  Google Scholar 

  7. De Smet PA, Smeets OS. Potential risks of health food products containing yohimbe extracts. BMJ. 1994;309:958.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Kunelius P, Hakkinen J, Lukkarinen O. Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double-blind crossover study. Urology. 1997;49:441–4.

    Article  CAS  PubMed  Google Scholar 

  9. Teloken C, Rhoden EL, Sogari P, Dambros M, Souto CA. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol. 1998;159:122–4.

    Article  CAS  PubMed  Google Scholar 

  10. Vogt HJ, Brandl P, Kockott G, et al. Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction. Int J Impot Res. 1997;9:155–61.

    Article  CAS  PubMed  Google Scholar 

  11. Pittler MH, Ernst E. Trials have shown yohimbine is effective for erectile dysfunction. BMJ. 1998;317:478.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol. 1998;159:433–6.

    Article  CAS  PubMed  Google Scholar 

  13. Himeno E, Ohyagi Y, Ma L, et al. Apomorphine treatment in Alzheimer mice promoting amyloid-beta degradation. Ann Neurol. 2011;69:248–56.

    Article  CAS  PubMed  Google Scholar 

  14. Lal S, Tesfaye Y, Thavundayil JX, et al. Apomorphine: clinical studies on erectile impotence and yawning. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13:329–39.

    Article  CAS  PubMed  Google Scholar 

  15. Lal S, Ackman D, Thavundayil JX, Kiely ME, Etienne P. Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry. 1984;8:695–9.

    Article  CAS  PubMed  Google Scholar 

  16. Lal S, Laryea E, Thavundayil JX, et al. Apomorphine-induced penile tumescence in impotent patients--preliminary findings. Prog Neuropsychopharmacol Biol Psychiatry. 1987;11:235–42.

    Article  CAS  PubMed  Google Scholar 

  17. Heaton JP, Morales A, Adams MA, Johnston B, El-Rashidy R. Recovery of erectile function by the oral administration of apomorphine. Urology. 1995;45:200–6.

    Article  CAS  PubMed  Google Scholar 

  18. Hsieh GC, Hollingsworth PR, Martino B, et al. Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine. J Pharmacol Exp Ther. 2004;308:330–8.

    Article  CAS  PubMed  Google Scholar 

  19. Gancher ST, Woodward WR, Boucher B, Nutt JG. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol. 1989;26:232–8.

    Article  CAS  PubMed  Google Scholar 

  20. Gancher ST, Bennett W, English J. Studies of renal function in animals chronically treated with apomorphine. Res Commun Chem Pathol Pharmacol. 1989;66:163–6.

    CAS  PubMed  Google Scholar 

  21. Pfeiffer RF, Gutmann L, Hull Jr KL, Bottini PB, Sherry JH, Investigators APOS. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:93–100.

    Article  PubMed  Google Scholar 

  22. Gontero P, D'Antonio R, Pretti G, et al. Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men. Int J Impot Res. 2005;17:80–5.

    Article  CAS  PubMed  Google Scholar 

  23. Pavone C, Curto F, Anello G, Serretta V, Almasio PL, Pavone-Macaluso M. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. J Urol. 2004;172:2347–9.

    Article  CAS  PubMed  Google Scholar 

  24. Eardley I. New oral therapies for the treatment of erectile dysfunction. Br J Urol. 1998;81:122–7.

    Article  CAS  PubMed  Google Scholar 

  25. Krege S, Goepel M, Sperling H, Michel MC. Affinity of trazodone for human penile alpha1-andalpha2-adrenoceptors. BJU Int. 2000;85:959–61.

    Article  CAS  PubMed  Google Scholar 

  26. Fink HA, MacDonald R, Rutks IR, Wilt TJ. Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU Int. 2003;92:441–6.

    Article  CAS  PubMed  Google Scholar 

  27. Kurt U, Ozkardes H, Altug U, Germiyanoglu C, Gurdal M, Erol D. The efficacy of anti-serotoninergic agents in the treatment of erectile dysfunction. J Urol. 1994;152:407–9.

    CAS  PubMed  Google Scholar 

  28. Montorsi F, Strambi LF, Guazzoni G, et al. Effect of yohimbine-trazodone on psychogenic impotence: a randomized, double-blind, placebo-controlled study. Urology. 1994;44:732–6.

    Article  CAS  PubMed  Google Scholar 

  29. Stryjer R, Spivak B, Strous RD, et al. Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study. Clin Neuropharmacol. 2009;32:82–4.

    Article  CAS  PubMed  Google Scholar 

  30. Taneja R. A rational combination pharmacotherapy in men with erectile dysfunction who initially failed to oral sildenafil citrate alone: a pilot study. J Sex Med. 2007;4:1136–41.

    Article  CAS  PubMed  Google Scholar 

  31. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995;75:191–236.

    CAS  PubMed  Google Scholar 

  32. Andersson KE. Pharmacology of penile erection. Pharmacol Rev. 2001;53:417–50.

    CAS  PubMed  Google Scholar 

  33. Andersson KE. Neurophysiology/pharmacology of erection. Int J Impot Res. 2001;13 Suppl 3:S8–17.

    Article  PubMed  Google Scholar 

  34. Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;381:153–65.

    Article  CAS  PubMed  Google Scholar 

  35. Clement P, Giuliano F. Anatomy and physiology of genital organs—men. Handb Clin Neurol. 2015;130:19–37.

    Article  PubMed  Google Scholar 

  36. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am. 2005;32:379–95. v.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Burnett AL. Role of nitric oxide in the physiology of erection. Biol Reprod. 1995;52:485–9.

    Article  CAS  PubMed  Google Scholar 

  38. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8:47–52.

    CAS  PubMed  Google Scholar 

  39. Sung BJ, Hwang KY, Jeon YH, et al. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature. 2003;425:98–102.

    Article  CAS  PubMed  Google Scholar 

  40. Wallis RM. The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5. Nihon Yakurigaku Zasshi. 1999;114 Suppl 1:22P–6.

    Article  PubMed  Google Scholar 

  41. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract. 2002;56:453–9.

    CAS  PubMed  Google Scholar 

  42. Carrier S. Pharmacology of phosphodiesterase 5 inhibitors. Can J Urol. 2003;10 Suppl 1:12–6.

    PubMed  Google Scholar 

  43. Staff P, editor. (2015). Physicians’ desk reference. 69th ed. PDR Network; 2015.

    Google Scholar 

  44. Bischoff E. Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int J Impot Res. 2004;16 Suppl 1:S34–7.

    Article  CAS  PubMed  Google Scholar 

  45. Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol. 2003;43:260–7.

    Article  CAS  PubMed  Google Scholar 

  46. Setter SM, Iltz JL, Fincham JE, Campbell RK, Baker DE. Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann Pharmacother. 2005;39:1286–95.

    Article  CAS  PubMed  Google Scholar 

  47. Coward RM, Carson CC. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag. 2008;4:1315–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Kyle JA, Brown DA, Hill JK. Avanafil for erectile dysfunction. Ann Pharmacother. 2013;47:1312–20.

    Article  CAS  PubMed  Google Scholar 

  49. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int. 2005;96:257–80.

    Article  CAS  PubMed  Google Scholar 

  50. Wang H, Yuan J, Hu X, Tao K, Liu J, Hu D. The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis. Curr Med Res Opin. 2014;30:1565–71.

    Article  CAS  PubMed  Google Scholar 

  51. Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63:902–12.

    Article  CAS  PubMed  Google Scholar 

  52. Hellstrom WJ, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl. 2002;23:763–71.

    CAS  PubMed  Google Scholar 

  53. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168:1332–6.

    Article  CAS  PubMed  Google Scholar 

  54. Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res. 2001;13:192–9.

    Article  CAS  PubMed  Google Scholar 

  55. Hatzichristou D, Cuzin B, Martin-Morales A, et al. Vardenafil improves satisfaction rates, depressive symptomatology, and self-confidence in a broad population of men with erectile dysfunction. J Sex Med. 2005;2:109–16.

    Article  CAS  PubMed  Google Scholar 

  56. Montorsi F, Althof SE. Partner responses to sildenafil citrate (viagra) treatment of erectile dysfunction. Urology. 2004;63:762–7.

    Article  PubMed  Google Scholar 

  57. Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res. 1999;43:521–31.

    Article  CAS  PubMed  Google Scholar 

  58. Chen J, Wollman Y, Chernichovsky T, Iaina A, Sofer M, Matzkin H. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. BJU Int. 1999;83:269–73.

    Article  CAS  PubMed  Google Scholar 

  59. Choi HK, Seong DH, Rha KH. Clinical efficacy of Korean red ginseng for erectile dysfunction. Int J Impot Res. 1995;7:181–6.

    CAS  PubMed  Google Scholar 

  60. Hong B, Ji YH, Hong JH, Nam KY, Ahn TY. A double-blind crossover study evaluating the efficacy of korean red ginseng in patients with erectile dysfunction: a preliminary report. J Urol. 2002;168:2070–3.

    Article  CAS  PubMed  Google Scholar 

  61. Jiang Z, Hu B, Wang J, et al. Effect of icariin on cyclic GMP levels and on the mRNA expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in penile cavernosum. J Huazhong Univ Sci Technolog Med Sci. 2006;26:460–2.

    Article  CAS  PubMed  Google Scholar 

  62. Dell'Agli M, Galli GV, Dal Cero E, et al. Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008;71:1513–7.

    Article  PubMed  Google Scholar 

  63. Zhang ZB, Yang QT. The testosterone mimetic properties of icariin. Asian J Androl. 2006;8:601–5.

    Article  CAS  PubMed  Google Scholar 

  64. Laws KR, Sweetnam H, Kondel TK. Is Ginkgo biloba a cognitive enhancer in healthy individuals? A meta-analysis. Hum Psychopharmacol. 2012;27:527–33.

    Article  CAS  PubMed  Google Scholar 

  65. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009:CD003120.

    Google Scholar 

  66. Cohen AJ, Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther. 1998;24:139–43.

    Article  CAS  PubMed  Google Scholar 

  67. Corazza O, Martinotti G, Santacroce R, et al. Sexual enhancement products for sale online: raising awareness of the psychoactive effects of yohimbine, maca, horny goat weed, and Ginkgo biloba. Biomed Res Int. 2014;2014:841798.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Sikora RSM, Engelke B, et al. Randomized placebo-controlled study on the effects of oral treatment with gingko biloba extract in patients with erec-tile dysfunction. J Urol. 1998;159: 240A (Abstract #917).

    Google Scholar 

  69. Kang BJ, Lee SJ, Kim MD, Cho MJ. A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. Hum Psychopharmacol. 2002;17:279–84.

    Article  PubMed  Google Scholar 

  70. Wheatley D. Triple-blind, placebo-controlled trial of Ginkgo biloba in sexual dysfunction due to antidepressant drugs. Hum Psychopharmacol. 2004;19:545–8.

    Article  PubMed  Google Scholar 

  71. Kushner FG, Hand M, Smith Jr SC, et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-Elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271–306.

    Article  PubMed  Google Scholar 

  72. Clark AM, Catto S, Bowman G, Macintyre PD. Design matters in secondary prevention: individualization and supervised exercise improves the effectiveness of cardiac rehabilitation. Eur J Cardiovasc Prev Rehabil. 2011;18:761–9.

    Article  PubMed  Google Scholar 

  73. Rosen RC, Jackson G, Kostis JB. Erectile dysfunction and cardiac disease: recommendations of the second princeton conference. Curr Urol Rep. 2006;7:490–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Northwestern University, Feinberg School of Medicine, 303 E. Chicago Ave., Suite 16-703, Chicago, IL, 60611, USA

    Nelson E. Bennett Jr. MD, FACS

Authors
  1. Nelson E. Bennett Jr. MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nelson E. Bennett Jr. MD, FACS .

Editor information

Editors and Affiliations

  1. Southern Illinois University School of Medicine, Springfield, Illinois, USA

    Tobias S. Köhler

  2. Division of Urology Department of Surgery, Southern Illinois University School of Medicine Hospital Affiliates, Springfield, Illinois, USA

    Kevin T. McVary

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Bennett, N.E. (2016). Oral Prescription Therapy for Erectile Dysfunction. In: Köhler, T., McVary, K. (eds) Contemporary Treatment of Erectile Dysfunction. Contemporary Endocrinology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-31587-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-31587-4_12

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-31585-0

  • Online ISBN: 978-3-319-31587-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation